EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

LUCIA failed its primary endpoint of statistical non-inferiority to on-label aflibercept for mean change in best-corrected visual acuity (BCVA), although patients demonstrated visual improvement. The trial met key secondary endpoints, including a reported 38% reduction in treatment burden; the excerpt does not provide the associated nominal p-value.